In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.from Moneycontrol Business News https://ift.tt/3azKKTG
No comments:
Post a Comment